AMENDED AND RESTATED SUPPLY AGREEMENTSupply Agreement • November 6th, 2007 • NUCRYST Pharmaceuticals Corp. • Surgical & medical instruments & apparatus • Alberta
• When tested against Pseudomonas aeruginosa and Staphylococcus aureus in 2 hours achieves at least a 4.0 log reduction at time zero and a log reduction of 3.0 throughout the shelf life. Reference WI-8.2.4-2.017.
SECOND AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENT This agreement made as of the 30th day of September, 2007.License and Development Agreement • November 6th, 2007 • NUCRYST Pharmaceuticals Corp. • Surgical & medical instruments & apparatus • Alberta
NUCRYST PHARMACEUTICALS CORP., (formerly Westaim Biomedical Corp.) a corporation incorporated under the laws of Alberta, and NUCRYST PHARMACEUTICAL INC., (formerly Westaim Biomedical Inc.) a corporation incorporated under the laws of the State of Delaware in the United States of America
